NCT03158129View on ClinicalTrials.gov

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

November 13, 2024

Study Completion Date

November 13, 2024

Conditions
Stage I Lung Non-Small Cell Cancer AJCC v7Stage IA Lung Non-Small Cell Carcinoma AJCC v7Stage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7Stage IIA Lung Non-Small Cell Carcinoma AJCC v7Stage IIB Lung Non-Small Cell Carcinoma AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

DRUG

Docetaxel

Given IV

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Pemetrexed

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03158129 - Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter